ARA-C AND AMSA FOR TREATMENT OF RELAPSED AND REFRACTORY ACUTE MYELOID-LEUKEMIA

被引：0
|
作者：
JAGER, U
LECHNER, K
SCHWARZINGER, I
BETTELHEIM, P
BOGNAR, H
GEISSLER, K
HAAS, O
HINTERBERGER, W
KOS, M
LEITHA, T
NEUMANN, E
PANZER, S
POLLAK, C
机构：
[1] VIENNA UNIV,DEPT MED 1,A-1010 VIENNA,AUSTRIA
[2] ST ANNA CHILDRENS HOSP,VIENNA,AUSTRIA
来源：
BLUT | 1986年 / 53卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：145 / 145
页数：1
相关论文
共 50 条
  • [21] Amonafide and ara-C treatment for secondary acute myeloid leukemia (sAML)
    Erba, H. P.
    Rizzieri, D. A.
    O'Donnell, M. R.
    Lundberg, A. S.
    Ajami, A. M.
    Rampersad, A. D.
    Capizzi, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Pilot trial of Mylotarg, Topotecan and Ara-C in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Alvarez, RH
    Estey, EH
    Kantarjian, HM
    Giles, FJ
    Beran, M
    Thomas, D
    Cortes, JE
    BLOOD, 2002, 100 (11) : 340A - 341A
  • [23] A Phase 1 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Ara-C in Patients with Relapsed or Refractory Acute Myeloid Leukemia
    DeAngelo, Daniel J.
    Fathi, Amir T.
    Werner, Lillian
    Avigan, David
    Luptakova, Katarina
    Wadleigh, Martha
    Steensma, David P.
    Hobbs, Gabriela Soriano
    Attar, Eyal C.
    Amrein, Philip C.
    Stone, Richard M.
    Ballen, Karen K.
    BLOOD, 2015, 126 (23)
  • [24] THE MANAGEMENT OF RELAPSED AND REFRACTORY ACUTE MYELOID-LEUKEMIA IN ADULTS
    JONES, L
    NEWLAND, AC
    LEUKEMIA & LYMPHOMA, 1991, 4 (02) : 93 - 98
  • [25] ETOPOSIDE (VP-16) AND CYTOSINE-ARABINOSIDE (ARA-C) COMBINATION FOR SECONDARY AND RELAPSED ACUTE MYELOID-LEUKEMIA (AML)
    LAZZARINO, M
    MORRA, E
    INVERARDI, D
    ALESSANDRINO, EP
    BERNASCONI, P
    MERANTE, S
    BERNASCONI, C
    LEUKEMIA RESEARCH, 1986, 10 (01) : 111 - 111
  • [26] LOW-DOSE CYTARABINE (ARA-C) IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID-LEUKEMIA (AML)
    MUFTI, GJ
    OSCIER, DG
    HAMBLIN, TJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1985, 61 (03) : 571 - 571
  • [27] CURATIVE EFFECT AND SAFETY OF 2-CDA, ARA-C AND G-CSF COMBINED TREATMENT FOR RELAPSED REFRACTORY ACUTE MYELOID LEUKEMIA
    Zhang, Xiaoxiang
    Chen, Ying
    Shou, Lihong
    Yang, Jianghua
    ACTA MEDICA MEDITERRANEA, 2021, 37 (01): : 163 - 167
  • [28] Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (Meca) in refractory and relapsed acute leukemia
    Ferrá, C
    Berlanga, JJ
    Gallardo, D
    Ancín, I
    Marín, D
    González, JR
    Peris, J
    Muñoz, J
    Sarrá, J
    Grañena, A
    LEUKEMIA & LYMPHOMA, 2000, 39 (5-6) : 583 - 590
  • [29] Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia
    DelaSerna, J
    Tomas, JF
    Solano, C
    DeParedes, MLG
    Campbell, J
    Grande, C
    DiazMediavilla, J
    LEUKEMIA & LYMPHOMA, 1997, 25 (3-4) : 365 - 372
  • [30] LONG-TERM RESULTS IN ACUTE MYELOID-LEUKEMIA TREATED WITH CONVENTIONAL DAUNORUBICIN, ARA-C (DA) AND THIOGUANINE, ARA-C, DAUNORUBICIN (TAD) POLYCHEMOTHERAPY
    FREUND, M
    LINK, H
    BODENSTEIN, H
    POLIWODA, H
    BLUT, 1986, 53 (03): : 241 - 241
12345